title: Severe pre-eclampsia and hypertensive crises.
abstract: Hypertensive disorders of pregnancy are one of the leading causes of peripartum morbidity and mortality globally. Hypertensive disease in pregnancy is associated with a spectrum of severity, ranging from mild pregnancy-induced hypertension to eclampsia. Although most cases of pre-eclampsia may be managed successfully, severe pre-eclampsia is a life-threatening multisystem disease associated with eclampsia, HELLP (haemolysis, elevated liver enzymes, low platelets) syndrome, acute kidney injury, pulmonary oedema, placental abruption and intrauterine foetal death. Management of severe pre-eclampsia includes identification of high-risk patients, optimisation of antenatal care, early intervention and the identification and early management of complications. In the first instance, oral anti-hypertensive agents, including labetalol, nifedipine and methyldopa, should be tried. If oral anti-hypertensive agents have failed to adequately control blood pressure, intravenous anti-hypertensives should be considered. Commonly used intravenous anti-hypertensives include labetalol, hydralazine and glyceryl trinitrate. In addition to anti-hypertensive agents, close attention should be given to regular clinical examination, assessment of fluid balance, neurologic status and monitoring of other vital signs. Magnesium sulphate should be considered early to prevent seizures. Delivery of the baby is the definitive management of severe pre-eclampsia.
authors: Renal Section, Division of Immunology and Inflammation, Department of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK; Bloomsbury Institute of Intensive Care Medicine, University College London, Cruciform Building, London, Greater London NW1 2BU, UK. Electronic address: nish_arul@yahoo.com.
authors: N
authors: N
authors: Arulkumaran
authors: L
authors: L
authors: Lightstone
mesh_terms: D061605:Administration, Intravenous; D000284:Administration, Oral; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003422:Critical Care; D042241:Early Diagnosis; D004461:Eclampsia / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D017359:HELLP Syndrome / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D046110:Hypertension, Pregnancy-Induced / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D007741:Labetalol / Q000627:therapeutic use; D008278:Magnesium Sulfate / Q000627:therapeutic use; D008750:Methyldopa / Q000627:therapeutic use; D009543:Nifedipine / Q000627:therapeutic use; D005996:Nitroglycerin / Q000627:therapeutic use; D011225:Pre-Eclampsia / Q000175:diagnosis / Q000188:drug therapy; D011247:Pregnancy; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000959:Antihypertensive Agents; D006830:Hydralazine; D008750:Methyldopa; D008278:Magnesium Sulfate; D005996:Nitroglycerin; D009543:Nifedipine; D007741:Labetalol
keywords: hypertension; intensive care; pre-eclampsia